The Department of Laboratory Medicine and Pathology at the University of Minnesota Medical School is committed to bringing leading-edge basic and applied research and innovation to patient care.
The research-intensive faculty within the department have several major focus areas including cancer, immunology, cardiovascular disease, renal disease, diabetes, and genetics. The faculty consist of tenured associate and full professors, several of which currently hold endowed chairs or professorships. They interface with University of Minnesota departments and centers such as the Center for Immunology, Masonic Cancer Center, and the Institute for Translational Neuroscience.
Brenner tumor (IHC for E-cadherin)
Products of conception: complete mole
Pap smear with endocervical adenocarcinoma in situ
Pancreatic ducta adenocarcinoma (neural invasion)
Lymph node with a micrometastasis form ductal carcinoma of the breast
Leydig cells (Reinke crystal)
Epithelioid trophoblastic tumor
Blue nevus of the endocervix
Gastroinstestinal stromal tumor (GIST) of the ileum
Stewart joins faculty as director of cytopathology
Jimmie Stewart III joined our anatomic pathology faculty on August 31 as an associate professor and director of cytopathology. He received an MD from the University of Arkansas for Medical Sciences where he also completed a post-sophomore year fellowship in pathology. He did his AP/CP residency at the University of Kentucky.
Post-residency he completed a fellowship in cytopathology at the University of Wisconsin, Madison, and an informatics fellowship at the University of Pittsburgh. Most recently Stewart was an associate professor at the University of Wisconsin, Madison.
Welcome Dr. Stewart!
Chief resident for 2015–16
PGY-4 residents Evan Sell and Sarah Drawz will be co-chief residents for the new academic year. Chief residents work with rotation directors at University of Minnesota Medical Center and our affiliates to develop each year’s training schedule. They also sit on the Residency and Fellowship Training Committee (RAFT) and help recruit the new class of residents.
In September 2015, the national media spotlight was focused on the Systolic Blood Pressure Intervention Trial (SPRINT). Results of the NIH-funded, multi-center clinical trial showed that intensive blood-pressure management reduced rates of heart attack, heart failure, and stroke by almost a third and the risk of death by almost a quarter, which prompted NIH to end the trial a year early.